RxDoctor Payments Data

Stephen Bernard, MD

Interventional Cardiology · Farmington, NMNPI 1306896246

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,185 of the $2,770 with a category attached, or 78.9%. 17 manufacturers reported payments, led by Medtronic at 24.8% of the total. That places this record below the midpoint for interventional cardiology clinicians in NM, where the typical reported total is $6,781.

$2,770in general payments, 2019–2025

Across 112 payments — averaging $24.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$687
  • Abiomed$658
  • Bard Peripheral Vascular, Inc.$279
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$273
  • Novartis$201
  • Abbott$113
  • plus $558 from 11 others

What the payments were for

  • Travel & lodging$54120%
  • Food & beverage$2,18579%
  • Education$432%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,770 in reported general payments places this provider in the 35th percentile of 25 interventional cardiology providers in New Mexico.

See all interventional cardiology providers in New Mexico

Medicare billing

Part B allowed, 2024
$136,405
Medicare patients
784
Services billed
1,709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$19,894
Atorvastatin Calcium48$812
Metoprolol Succinate48$740
ClopidogrelClopidogrel Bisulfate33$411
Amlodipine Besylate28$326
Lisinopril45$318
Losartan Potassium14$173
Hydrochlorothiazide12$77

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$19,89412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 25 interventional cardiology providers in New Mexico.

Other interventional cardiology in Farmington

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →